Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

It is known that growth hormone can induce accelerated bone turnover in GH deficient people as well as healthy elderly people.

In this study the researchers examined the effect of recombinant human GH (rhGH) on bone mineral mass and bone turnover in the presence of the bone resorption inhibiting agent, pamidronate.

Who Took Part

According to the abstract, 10 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

Bone mineral content (BMC) of the lumbar spine and femoral neck was measured with dual-energy X-ray absorptiometry and BMC of the distal and proximal forearm with single-photon absorptiometry.

Body composition was measured with bioelectrical impedance and total body dual-energy X-ray absorptiometry.

Serum IGF-I and biochemical indices of bone turnover were also measured.

What Was Measured

PubMed files the paper under topics including Body Composition, Bone Density, Bone Resorption, Diphosphonates, Growth Hormone, Insulin-Like Growth Factor I and Osteoporosis, Postmenopausal.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1995 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.